Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer

Alessandro Morabito, Guido Carillio, Raffaele Longo, Giampietro Gasparini

Research output: Contribution to journalArticle

Abstract

Experimental studies have demonstrated that thalidomide has anti-tumor activity mediated by blockage of angiogenesis, with clinical efficacy in multiple myeloma, glioblastoma multiforme, and renal cell cancer. We investigated the therapeutic activity and toxicity of thalidomide in patients with progressive metastatic breast cancer pretreated with chemotherapy. Inclusion criteria were metastatic breast cancer in progression of disease after at least two lines of chemotherapy, age > 18 years, performance status <2, and adequate hématologie, renal, and hepatic functions. Twelve patients entered the study, eight of whom were pretreated with three or more lines of chemotherapy (66.7%). Thalidomide was well tolerated: the most common side effects were constipation and somnolence (58.3% of patients). No objective response or durable stable disease was observed. Median time to progression and median overall survival were 8 weeks (range, 4-10 weeks) and 16 weeks (range, 8-54 weeks), respectively. In conclusion, thaiidomide is an ineffective treatment in patients with progressive metastatic breast cancer heavily pretreated with chemotherapy.

Original languageEnglish
Pages (from-to)248-251
Number of pages4
JournalCancer Journal (United States)
Volume11
Issue number3
Publication statusPublished - 1998

Fingerprint

Thalidomide
Breast Neoplasms
Drug Therapy
Constipation
Glioblastoma
Multiple Myeloma
Renal Cell Carcinoma
Disease Progression
Kidney
Survival
Liver
Therapeutics
Neoplasms

Keywords

  • Anticancer therapy
  • Breast cancer
  • Thalidomide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. / Morabito, Alessandro; Carillio, Guido; Longo, Raffaele; Gasparini, Giampietro.

In: Cancer Journal (United States), Vol. 11, No. 3, 1998, p. 248-251.

Research output: Contribution to journalArticle

Morabito, Alessandro ; Carillio, Guido ; Longo, Raffaele ; Gasparini, Giampietro. / Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. In: Cancer Journal (United States). 1998 ; Vol. 11, No. 3. pp. 248-251.
@article{2e570b3198e54fa6bbde8e6706508a9f,
title = "Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer",
abstract = "Experimental studies have demonstrated that thalidomide has anti-tumor activity mediated by blockage of angiogenesis, with clinical efficacy in multiple myeloma, glioblastoma multiforme, and renal cell cancer. We investigated the therapeutic activity and toxicity of thalidomide in patients with progressive metastatic breast cancer pretreated with chemotherapy. Inclusion criteria were metastatic breast cancer in progression of disease after at least two lines of chemotherapy, age > 18 years, performance status <2, and adequate h{\'e}matologie, renal, and hepatic functions. Twelve patients entered the study, eight of whom were pretreated with three or more lines of chemotherapy (66.7{\%}). Thalidomide was well tolerated: the most common side effects were constipation and somnolence (58.3{\%} of patients). No objective response or durable stable disease was observed. Median time to progression and median overall survival were 8 weeks (range, 4-10 weeks) and 16 weeks (range, 8-54 weeks), respectively. In conclusion, thaiidomide is an ineffective treatment in patients with progressive metastatic breast cancer heavily pretreated with chemotherapy.",
keywords = "Anticancer therapy, Breast cancer, Thalidomide",
author = "Alessandro Morabito and Guido Carillio and Raffaele Longo and Giampietro Gasparini",
year = "1998",
language = "English",
volume = "11",
pages = "248--251",
journal = "Cancer Journal from Scientific American",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "3",

}

TY - JOUR

T1 - Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer

AU - Morabito, Alessandro

AU - Carillio, Guido

AU - Longo, Raffaele

AU - Gasparini, Giampietro

PY - 1998

Y1 - 1998

N2 - Experimental studies have demonstrated that thalidomide has anti-tumor activity mediated by blockage of angiogenesis, with clinical efficacy in multiple myeloma, glioblastoma multiforme, and renal cell cancer. We investigated the therapeutic activity and toxicity of thalidomide in patients with progressive metastatic breast cancer pretreated with chemotherapy. Inclusion criteria were metastatic breast cancer in progression of disease after at least two lines of chemotherapy, age > 18 years, performance status <2, and adequate hématologie, renal, and hepatic functions. Twelve patients entered the study, eight of whom were pretreated with three or more lines of chemotherapy (66.7%). Thalidomide was well tolerated: the most common side effects were constipation and somnolence (58.3% of patients). No objective response or durable stable disease was observed. Median time to progression and median overall survival were 8 weeks (range, 4-10 weeks) and 16 weeks (range, 8-54 weeks), respectively. In conclusion, thaiidomide is an ineffective treatment in patients with progressive metastatic breast cancer heavily pretreated with chemotherapy.

AB - Experimental studies have demonstrated that thalidomide has anti-tumor activity mediated by blockage of angiogenesis, with clinical efficacy in multiple myeloma, glioblastoma multiforme, and renal cell cancer. We investigated the therapeutic activity and toxicity of thalidomide in patients with progressive metastatic breast cancer pretreated with chemotherapy. Inclusion criteria were metastatic breast cancer in progression of disease after at least two lines of chemotherapy, age > 18 years, performance status <2, and adequate hématologie, renal, and hepatic functions. Twelve patients entered the study, eight of whom were pretreated with three or more lines of chemotherapy (66.7%). Thalidomide was well tolerated: the most common side effects were constipation and somnolence (58.3% of patients). No objective response or durable stable disease was observed. Median time to progression and median overall survival were 8 weeks (range, 4-10 weeks) and 16 weeks (range, 8-54 weeks), respectively. In conclusion, thaiidomide is an ineffective treatment in patients with progressive metastatic breast cancer heavily pretreated with chemotherapy.

KW - Anticancer therapy

KW - Breast cancer

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=33749574123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749574123&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 248

EP - 251

JO - Cancer Journal from Scientific American

JF - Cancer Journal from Scientific American

SN - 1528-9117

IS - 3

ER -